Coccidioidomycosis-Pipeline Review, H1 2017

Coccidioidomycosis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9041IDB
  • |
  • Pages: 40
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Coccidioidomycosis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coccidioidomycosis-Pipeline Review, H1 2017, provides an overview of the Coccidioidomycosis (Infectious Disease) pipeline landscape.

Coccidioidomycosis, also called Valley fever, is an infection caused by the fungus Coccidioides. Symptoms include fever, cough, chest pain, chills, headache, fatigue and joint aches. Risk factors include weakened immune system, age, pregnancy, race and environmental exposure. Treatment includes antifungal medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coccidioidomycosis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Coccidioidomycosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coccidioidomycosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Coccidioidomycosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Coccidioidomycosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Coccidioidomycosis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Coccidioidomycosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Coccidioidomycosis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Coccidioidomycosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Coccidioidomycosis (Infectious Disease)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Coccidioidomycosis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Coccidioidomycosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Coccidioidomycosis-Overview

Coccidioidomycosis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Coccidioidomycosis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Coccidioidomycosis-Companies Involved in Therapeutics Development

Amplyx Pharmaceuticals Inc

Valley Fever Solutions Inc

Viamet Pharmaceuticals Inc

Coccidioidomycosis-Drug Profiles

Amphotericin B sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

coccidioidomycosis vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nikkomycin Z-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1161-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1598-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coccidioidomycosis-Dormant Projects

Coccidioidomycosis-Product Development Milestones

Featured News & Press Releases

Nov 16, 2016: FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections

Sep 15, 2016: FDA Grants QIDP Designation to VT-1598 for Treatment of Valley Fever

Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections

May 25, 2016: Viamet Receives Orphan Drug Designation from the FDA for VT-1598 for the Treatment of Coccidioidomycosis

May 20, 2015: Viamet Announces NIH Grant for Compounds Directed at Valley Fever

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Coccidioidomycosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Coccidioidomycosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Coccidioidomycosis-Pipeline by Amplyx Pharmaceuticals Inc, H1 2017

Coccidioidomycosis-Pipeline by Valley Fever Solutions Inc, H1 2017

Coccidioidomycosis-Pipeline by Viamet Pharmaceuticals Inc, H1 2017

Coccidioidomycosis-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Amplyx Pharmaceuticals Inc, Valley Fever Solutions Inc, Viamet Pharmaceuticals Inc

Coccidioidomycosis Therapeutic Products under Development, Key Players in Coccidioidomycosis Therapeutics, Coccidioidomycosis Pipeline Overview, Coccidioidomycosis Pipeline, Coccidioidomycosis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143120
Site License
USD 4000 INR 286240
Corporate User License
USD 6000 INR 429360

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com